AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in...
bionity.com     May 16, 2008            

16 May 2008 - AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH). Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist, is the Company's flagship... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

                   

BUYINS.NET: CHA, GBX, KERX, SGXP, SUPG, TRMD Have Been Removed From Naked Short List Today

tmcnet.com     Jul 11, 2008   20 related          

BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: China Telecom Corp. Ltd. (NYSE: CHA), The Greenbrier Companies Inc. (NYSE:...                

comments

                   

BUYINS.NET: KERX, MITI, OTEX, SDTH, SVNT, INBG Have Also Been Added To Naked Short List Today

tmcnet.com     Jul 2, 2008   24 related          

BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Micromet Inc. (NASDAQ: MITI), Open...                

comments

AEterna Zentaris Inc divests Quebec City building

m2.com     Jun 30, 2008          

AEterna Zentaris Inc (NASDAQ:AEZS) (TSX:AEZ), a biopharmaceutical company focused on endocrine therapy and oncology, declared on 27 June that the company has closed the sale of its Quebec City property for a purchase price of...                

comments

                   

Solid Tumor Space Companies Examined in Wall Street Transcript Biotechnology Report (Wall Street...

yahoo.com     Jun 27, 2008   3 related          

67 WALL STREET, New York - The Wall Street Transcript has just published its Biotechnology issue, a report offering a timely review of the sector to serious investors and industry executives. The full issue is available by...                

comments